Book online for a Covid-19 test at our drive-up center

Economic Times: GenePath Diagnostics develops quantitative COVID-19 test kit for drug makers

GenePath Diagnostics is very excited to announce the development and launch of the first of its kind quantitative RT-PCR test, which will enable therapeutic drug and vaccine makers to test the efficacy and accelerate the time to market for their products for Covid-19. This test is currently being used successfully by a few pharma companies building therapeutic drugs for Covid-19.

Read More

The Hindu: RT-PCR test kit of Pune firm gets nod for manufacture, sale in India

‘CoViDx One’, the COVID-19 RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction) test kit developed by Pune-based GenePath Diagnostics, has received approval for manufacture and sale in India from the Central Drugs Standard Control Organisation (CDSCO).

The approval was received on August 31, said a statement by the firm on Friday. The CDSCO has given approval to the Bengaluru-based Achira Labs to manufacture the kits.

Read More

Times of India: GenePath Diagnostics opens Pune's first drive-up Covid-19 test center

In an effort to make Covid-19 testing simpler and more accessible, a city-based diagnostics company GenePath Diagnostics has set up Pune's first drive-up Covid-19 sample collection center.

Read More

Sakal Times: We are delivering higher end of genetic testing for patients

Dr Nikhil Phadke, Founder and Chief Scientific Officer of GenePath diagnostics, in an interview with Namrata Devikar shared that there was a need for special diagnostic tests for Indian patients. Most genetic testing can be expensive and to reduce the overall cost, India needs to have specialised tests. The solutions provided by the company so far has helped medical professionals to provide a better line of treatment.

Read More

Sakal: A new health movement to reduce cervical cancer in India

In India, cervical cancer kills on average one woman every eight minutes. Screening for the Human Papillomavirus (HPV) can significantly reduce the incidence of this type of cancer. GenePath Diagnostics is working with I-SHARE towards the goal of reducing cervical cancer in India as per the WHO targets. This article by Dr. Nikhil Phadke speaks about the plan to attain this goal by using the highly sensitive HPV testing by DNA. This will be achieved with support from CSR initiatives, individual donors who would like to support the cause, NGOs working in this space who would like to collaborate, and doctors and hospitals serving needy patients.

Read More